Risk predictors for adverse COVID-19 outcomes in Latin American patients with autoimmune rheumatic diseases: A multicentre study in Ecuador and Mexico

Revista Colombiana de Reumatología (English Edition) Pub Date : 2025-04-01 DOI:10.1016/j.rcreue.2025.04.004

Santiago Guzmán-García , Goethe Sacoto-Flores , Johanna Román-Bermeo , Fabiana Samaniego-Burneo , María Ochoa , Franklin Uguña-Sari , Gladis Molina-Alvarado , Luis M. Amezcua-Guerra

{"title":"Risk predictors for adverse COVID-19 outcomes in Latin American patients with autoimmune rheumatic diseases: A multicentre study in Ecuador and Mexico","authors":"Santiago Guzmán-García , Goethe Sacoto-Flores , Johanna Román-Bermeo , Fabiana Samaniego-Burneo , María Ochoa , Franklin Uguña-Sari , Gladis Molina-Alvarado , Luis M. Amezcua-Guerra","doi":"10.1016/j.rcreue.2025.04.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction/objectives</h3><div>The understanding of COVID-19 progression among patients with autoimmune rheumatic diseases (SARDs) in Latin America remains limited. This study aimed to identify risk predictors associated with poor outcomes of COVID-19 in patients with SARDs.</div></div><div><h3>Materials and methods</h3><div>An observational multicentre study including patients with SARDs from Ecuador and Mexico.</div></div><div><h3>Results</h3><div>A total of 103 patients (78% women), aged 52.5±17.7 years, were enrolled. The most prevalent SARDs were rheumatoid arthritis (59%) and systemic lupus erythematosus (SLE; 24%). Severe COVID-19 was observed in 28% of patients at admission, 43% experienced complications during follow-up, and 8% ultimately died. Mortality rates were highest in patients with antiphospholipid syndrome (27%) or SLE (20%). Poor prognostic factors included acute respiratory distress syndrome (odds ratio [OR]=17.07), severe COVID-19 at admission (OR=11.45), and presence of SLE (OR=4.62). In multivariate analysis, SLE emerged as the sole predictor of mortality (OR=15.61).</div></div><div><h3>Conclusions</h3><div>Patients with SARDs in Latin America face significant risks of adverse COVID-19 outcomes, with SLE being a major risk factor for mortality.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 152-158"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Reumatología (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444440525000238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction/objectives

The understanding of COVID-19 progression among patients with autoimmune rheumatic diseases (SARDs) in Latin America remains limited. This study aimed to identify risk predictors associated with poor outcomes of COVID-19 in patients with SARDs.

Materials and methods

An observational multicentre study including patients with SARDs from Ecuador and Mexico.

Results

A total of 103 patients (78% women), aged 52.5 ± 17.7 years, were enrolled. The most prevalent SARDs were rheumatoid arthritis (59%) and systemic lupus erythematosus (SLE; 24%). Severe COVID-19 was observed in 28% of patients at admission, 43% experienced complications during follow-up, and 8% ultimately died. Mortality rates were highest in patients with antiphospholipid syndrome (27%) or SLE (20%). Poor prognostic factors included acute respiratory distress syndrome (odds ratio [OR] = 17.07), severe COVID-19 at admission (OR = 11.45), and presence of SLE (OR = 4.62). In multivariate analysis, SLE emerged as the sole predictor of mortality (OR = 15.61).

Conclusions

Patients with SARDs in Latin America face significant risks of adverse COVID-19 outcomes, with SLE being a major risk factor for mortality.

查看原文本刊更多论文

拉丁美洲自身免疫性风湿病患者COVID-19不良结局的风险预测因素：厄瓜多尔和墨西哥的一项多中心研究

在拉丁美洲，对自身免疫性风湿病（SARDs）患者中COVID-19进展的了解仍然有限。本研究旨在确定与急性呼吸窘迫综合征患者COVID-19预后不良相关的风险预测因素。材料和方法一项多中心观察性研究，包括来自厄瓜多尔和墨西哥的急性呼吸窘迫综合征患者。结果共纳入103例患者（78%为女性），年龄52.5±17.7岁。最常见的SARDs是类风湿关节炎（59%）和系统性红斑狼疮(SLE；24%)。入院时，28%的患者出现严重的COVID-19, 43%的患者在随访期间出现并发症，8%的患者最终死亡。抗磷脂综合征（27%）或SLE（20%）患者的死亡率最高。不良预后因素包括急性呼吸窘迫综合征（比值比[OR] = 17.07）、入院时严重的COVID-19 （OR = 11.45）和存在SLE （OR = 4.62）。在多变量分析中，SLE成为死亡率的唯一预测因子（OR = 15.61）。结论拉丁美洲的SARDs患者面临COVID-19不良结局的显著风险，SLE是死亡的主要危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Colombiana de Reumatología (English Edition)

自引率

0.00%

发文量